Webinars
ADME 101: Biobank Fatty Liver Disease Tissues and Their Exploration in Microarrays
Presenter: Maciej Czerwinski, Ph.D., XenoTech Director of Consulting This ADME 101 discusses biobank tissue and its research applications. The Research Biobank was established to preserve,...
ADME 101: Enzyme Induction Studies
The clearance of a drug can be increased and its effectiveness or safety compromised if it is co-administered with a second drug that induces the enzyme responsible...
ADME 101: Which Hepatocyte Test System Should I Use?
Presented by Chris Bohl, Ph.D., Global Technical Support Manager This ADME 101 video provides an overview of different types of hepatocytes, their unique benefits, and...
ADME 101: Efflux and Uptake Drug Transporters
Presented by Andrew Taylor, Ph.D., Services Technical Support Manager Drug transport can be thought of as the AD&E in ADME, as transporters are responsible for absorption, distribution,...
ADME 101: Reaction Phenotyping Studies in Drug Metabolism
Presenter: Andrew Taylor, Ph.D., Services Technical Support Manager It is important to identify the enzymes that significantly contribute to the metabolism of a drug candidate...
ADME 101: Lysosomal Trapping
Presenter: Andrew Taylor, Ph.D., Services Technical Support Manager This ADME 101 video discusses how compounds can become trapped by lysosomes, which can lead to high...
ADME 101: Guide to Subcellular Fractions and When to Use Which Test System
Presenter: Chris Bohl, Ph.D., Global Technical Support Manager This ADME 101 video provides an overview of different types of subcellular fractions, such as microsomes, S9,...
In Vitro Inhibition Studies: Elements of Design and Important Considerations in Data Analysis
Presenter: Jennifer Horkman, Senior Scientist in Program Oversight at XenoTech When evaluating drug-drug interaction (DDI) risk of an investigational drug, a battery of studies is needed to investigate victim/perpetrator...
Comparison Between the Final US FDA, Japan PMDA, and EMA In Vitro DDI Guidance Documents: Are We Finally Harmonized?
Presenter: Brian Ogilvie, Ph.D., XenoTech Vice President of Scientific Consulting In January, the FDA published its final guidance for industry on in vitro drug-drug interaction (DDI) studies. Dr. Ogilvie will...
In Vitro ADME & Drug-Drug Interaction Considerations for Toxicologists
In vitro ADME and drug-drug interaction (DDI) investigations are early activities in the drug development process that are critical for framing downstream decision making. This ADME 101 webinar will provide insights at a high-level related to regulatory drivers, investigatory objectives, and practical concerns for such studies that are relevant to interested general toxicologists. Participants will gain insight as to the critical need and utility for in vitro ADME and DDI investigations as related to drug development. Regulatory expectations will be reviewed as will points of particular interest for enabling successful achievement of investigatory goals...